Based on these results, the FDA approved the drug pembrolizumab in the first-line therapy of advanced NSCLC for ≥50% PD-L1 expression without the presence of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase gene (ALK) rearrangement [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.